Evidence map›Paper›PMID 34169384›Full record

ArticleBiochemical genetics2022

miR-181b-5p Promotes the Progression of Cholangiocarcinoma by Targeting PARK2 via PTEN/PI3K/AKT Signaling Pathway.

Zhe-Long Jiang, Fu-Xing Zhang, Hong-Liang Zhan, He-Jun Yang, Si-Yu Zhang, Zhao-Hui Liu, Yi Jiang, Li-Zhi Lv, Rui-Sheng Ke

Abstract read
PubMed Publisher
In one paragraph

Article in Biochemical genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. The diverse roles of circular RNAs in cholangiocarcinoma.Medical oncology (Northwood, London, England) · 2025
    Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Zhe-Long Jiang *Department of Hepatobiliary Surgery, 900 Hospital of the Joint Logistics Team, No. 156 The Second West Ring Road, Fuzhou City, 350025, Fujian Province, China.
Fu-Xing Zhang *Department of General Surgery, The First Affiliated Hospital of Xiamen University, No. 55 The Zhenhai Road, Siming District, Xiamen, 361001, Fujian Province, China.
Hong-Liang ZhanDepartment of General Surgery, The First Affiliated Hospital of Xiamen University, No. 55 The Zhenhai Road, Siming District, Xiamen, 361001, Fujian Province, China.
He-Jun YangDepartment of Hepatobiliary Surgery, 900 Hospital of the Joint Logistics Team, No. 156 The Second West Ring Road, Fuzhou City, 350025, Fujian Province, China.
Si-Yu ZhangDepartment of General Surgery, The First Affiliated Hospital of Xiamen University, No. 55 The Zhenhai Road, Siming District, Xiamen, 361001, Fujian Province, China.
Zhao-Hui LiuDepartment of General Surgery, The First Affiliated Hospital of Xiamen University, No. 55 The Zhenhai Road, Siming District, Xiamen, 361001, Fujian Province, China.
Yi JiangDepartment of Hepatobiliary Surgery, 900 Hospital of the Joint Logistics Team, No. 156 The Second West Ring Road, Fuzhou City, 350025, Fujian Province, China.
Li-Zhi Lv *Department of Hepatobiliary Surgery, 900 Hospital of the Joint Logistics Team, No. 156 The Second West Ring Road, Fuzhou City, 350025, Fujian Province, China. gdxzlj@126.com.
Rui-Sheng KeDepartment of General Surgery, The First Affiliated Hospital of Xiamen University, No. 55 The Zhenhai Road, Siming District, Xiamen, 361001, Fujian Province, China. ringsonke@163.com.ORCID http://orcid.org/0000-0001-9269-4692
First Affiliated Hospital of Xiamen University · CNFujian Medical University · CN

Funding

the 900 Hospital Innovation Team Construction Special Funding No. 2018J02the 900 Hospital Innovation Team Construction Special Funding No.2018Q06the Fujian Natural Science Foundation (Youth Innovation) Project No. 2020J05299The Key Project of Natural Science Foundation of Fujian Province No. 2019Y0068Xiamen Medical and Health Guiding Project Fund Project No. 3502Z20209011
6 · The paper itself

Abstract

This study combined with bioinformatics analysis and investigated the expression pattern of miR-181b-5p, as well as explored its role and mechanism in cholangiocarcinoma (CCA or CHOL). Several bioinformatics databases were used to analyze the expression of miR-181b and the enrichment of miR-181b in biological activities and biological pathways in CCA. The RT-qPCR analysis was used to examine the expression levels of miR-181b-5p. A receiver operation characteristics (ROC) curve analysis and the Kaplan-Meier survival assay were conducted to validate the diagnostic and prognostic implication of miR-181b-5p. Cell experiments were used to explore the possible functional role of miR-181b-5p in CCA progression. The bioinformatics assay was used to predict the target gene of miR-181b-5p and Western blot was used to confirm the related signaling pathway. The bioinformatics analysis results suggest that miR-181b-5p was highly expressed in cholangiocarcinoma and its expression was negatively related to PARK2 expression in CCA tissues. miR-181b-5p expression in the serum and tissues was upregulated and associated with lymph node metastasis and TNM stage. Increased expression of miR-181b-5p had relatively high diagnostic accuracy and showed poor prognosis in CCA patients. In addition, miR-181b-5p overexpression enhanced cell proliferation, migration, and invasion by targeting PARK2. Overexpression of miR-181b-5p activated the PI3K/AKT signaling pathway, while knockdown of miR-181b-5p suppressed the signaling pathway. Increased expression of miR-181b-5p in CCA may be a potential diagnostic or/and prognostic indicator for CCA patients. The present data indicated miR-181b-5p acted as an oncogene in CCA through promoting tumor cell proliferation, migration, and invasion of CCA via the PTEN/PI3K/AKT signaling pathway by targeting PARK2, which might be a promising therapeutic target or biomarker for CCA.

Indexed as

Bile Duct NeoplasmsCholangiocarcinomaMicroRNAsCell Line, TumorCell MovementCell ProliferationHumansPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktPTEN PhosphohydrolaseSignal TransductionUbiquitin-Protein LigasesMicroRNAsMIrn181 microRNA, humanparkin proteinPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktPTEN PhosphohydrolasePTEN protein, humanUbiquitin-Protein LigasesBioinformatics analysisCholangiocarcinomaDiagnosis and prognosismiR-181b-5pMolecular mechanism

Identifiers

PMID34169384
OpenAlexW3176661419

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.